Real-world Evaluation of Tolerability, Safety and Efficacy of Rivastigmine Oral Solution in Patients with Mild to Moderate Alzheimer’s Disease Dementia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: The purpose of this study is to investigate the safety, tolerability and efficacy of titrating dose of rivastigmine oral solution in patients with mild to moderate Alzheimer’s disease (AD) in Taiwan. Methods: We recruited 108 mild to moderate AD patients with RivastⓇ (rivastigmine oral solution 2 mg/ml) treatment for 52 weeks. We recorded the demographic characteristics, initial cognition by mini-mental state examination (MMSE), initial global status by clinical dementia rating (CDR) with CDR-Sum of Boxes (CDR-SB), initial dose, and titrating dose at each visit. We investigated the adherence, proportion of possible side effects, optimal dose, and time to optimal dose. We demonstrated the proportion of cognitive decline and its possible risk factors. Results: During the course, 9 patients discontinued the rivastigmine oral solution due to poor compliance or preference. Twelve out of 99 patients (12.1%) reported possible side effects. Among 87 patients, the mean age was 77.2 ± 9.0 years ago with female predominant (65.2%). The optimal dose was 3.6 ± 1.4 ml in average and 4 ml (n = 31, 35.6%) in mode. The duration to optimal dose was 12.5 ± 10.2 weeks and 24 weeks (n = 35, 40.2%) in mode. It presented 25% with cognitive decline in MMSE, 27% with global function decline in CDR and 63% with global function decline in CDR-SB. Conclusion: We demonstrated the clinical experience of rivastigmine oral solution in mild to moderate AD patients. It suggested rivastigmine oral solution 4ml is the optimal dose with 24 weeks to the optimal dose for at least one third of patients.
Abstract
Objective: The purpose of this study is to investigate the safety, tolerability and efficacy of titrating dose of rivastigmine oral solution in patients with mild to moderate Alzheimer’s disease (AD) in Taiwan. Methods: We recruited 108 mild to moderate AD patients with RivastⓇ (rivastigmine oral solution 2 mg/ml) treatment for 52 weeks. We recorded the demographic characteristics, initial cognition by mini-mental state examination (MMSE), initial global status by clinical dementia rating (CDR) with CDR-Sum of Boxes (CDR-SB), initial dose, and titrating dose at each visit. We investigated the adherence, proportion of possible side effects, optimal dose, and time to optimal dose. We demonstrated the proportion of cognitive decline and its possible risk factors. Results: During the course, 9 patients discontinued the rivastigmine oral solution due to poor compliance or preference. Twelve out of 99 patients (12.1%) reported possible side effects. Among 87 patients, the mean age was 77.2 ± 9.0 years ago with female predominant (65.2%). The optimal dose was 3.6 ± 1.4 ml in average and 4 ml (n = 31, 35.6%) in mode. The duration to optimal dose was 12.5 ± 10.2 weeks and 24 weeks (n = 35, 40.2%) in mode. It presented 25% with cognitive decline in MMSE, 27% with global function decline in CDR and 63% with global function decline in CDR-SB. Conclusion: We demonstrated the clinical experience of rivastigmine oral solution in mild to moderate AD patients. It suggested rivastigmine oral solution 4ml is the optimal dose with 24 weeks to the optimal dose for at least one third of patients.
참고문헌 (51)
- Gauthier S, "Advances in the pharmacotherapy of Alzheimer’s disease", CMAJ, 166, pp.616~623 (2002)
- Wang HY, "beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology", J Biol Chem, 275, pp.5626~5632 (2000)
- "Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life. American Psychiatric Association", Am J Psychiatry, 154(5 Suppl), pp.1~39 (1997)
- Small GW, "Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society", JAMA, 278, pp.1363~1371 (1997)
- Doody RS, "Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology", Neurology, 56, pp.1154~1166 (2001)
- Cummings JL, "Guidelines for managing Alzheimer’s disease:part I. Assessment", Am Fam Physician, 65, pp.2263~2272 (2002)
- Cummings JL, "Guidelines for managing Alzheimer’s disease:part II. Treatment", Am Fam Physician, 65, pp.2525~2534 (2002)
- Grossberg GT, "Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications", Int J Geriatr Psychiatry, 15, pp.242~247 (2000)
- Polinsky RJ, "Clinical pharmacology of rivastigmine : a newgeneration acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease", Clin Ther, 20, pp.634~647 (1998)
- Bullock R, "The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action : an hypothesis", Int J Clin Pract, 56, pp.206~214 (2002)
- Onor ML, "Rivastigmine in the treatment of Alzheimer’s disease : an update", Clin Interv Aging, 2, pp.17~32 (2007)
- Rösler M, "Efficacy and safety of rivastigmine in patients with Alzheimer’s disease : international randomised controlled trial", BMJ, 318, pp.633~638 (1999)
- Farlow M, "A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease", Eur Neurol, 44, pp.236~241 (2000)
- Small G, "Defining optimal treatment with cholinesterase inhibitors in Alzheimer’s disease", Alzheimers Dement, 7, pp.177~184 (2011)
- Imbimbo BP, "Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer’s disease", CNS Drugs, 15, pp.375~390 (2001)
- Lefèvre G, "Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects", J Clin Pharmacol, 48, pp.246~252 (2008)
- Cumbo E, "Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer’s disease : a 12-month, randomized, open-label trial", J Alzheimers Dis, 39, pp.477~485 (2014)
- Blanco-Silvente L, "Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer’s disease : a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients", Int J Neuropsychopharmacol, 20, pp.519~528 (2017)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV)", pp.143~147 (1994), American Psychiatric Association
- McKhann G, "Clinical diagnosis of Alzheimer’s disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
- Yang YH, "Vascular contribution to cognition in stroke and Alzheimer’s disease", Brain Sci Adv, 4, pp.39~48 (2018)
- Morris JC, "The Clinical Dementia Rating(CDR) : current version and scoring rules", Neurology, 43, pp.2412~2414 (1993)
- Folstein MF, "“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician", J Psychiatr Res, 12, pp.189~198 (1975)
- Wattmo C, "Predictors of long-term cognitive outcome in Alzheimer’s disease", Alzheimers Res Ther, 3, pp.23~ (2011)
- Birks J, "Rivastigmine for Alzheimer’s disease", Cochrane Database Syst Rev, (2), pp.CD001191~ (2009)
- O’Bryant SE, "Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the na-tional Alzheimer’s coordinating center database", Arch Neurol, 67, pp.746~749 (2010)
- O’Bryant SE, "Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores : a Texas Alzheimer’s research consortium study", Arch Neurol, 65, pp.1091~1095 (2008)
- Chen TH, "Factors affecting therapeutic response to rivastigmine in Alzheimer’s disease patients in Taiwan", Kaohsiung J Med Sci, 33, pp.277~283 (2017)
- Strittmatter WJ, "Apolipoprotein E and Alzheimer’s disease", Annu Rev Neurosci, 19, pp.53~77 (1996)
- Michaelson DM, "APOE 4 : the most prevalent yet understudied risk factor for Alzheimer’s disease", Alzheimers Dement, 10, pp.861~868 (2014)
- Holtzman DM, "Apolipoprotein E and apolipoprotein E receptors : normal biology and roles in Alzheimer disease", Cold Spring Harb Perspect Med, 2, pp.a006312~ (2012)
- Di Battista AM, "Alzheimer’s disease genetic risk factor APOE-4 also affects normal brain function", Curr Alzheimer Res, 13, pp.1200~1207 (2016)
- Safieh M, "ApoE4 : an emerging therapeutic target for Alzheimer’s disease", BMC Med, 17, pp.64~ (2019)
- Cerejeira J, "Behavioral and psychological symptoms of dementia", Front Neurol, 3, pp.73~ (2012)
- Ali Hosseini-Sharifabad, "Magnesium Increases the Protective Effect of Citicoline on Aluminum Chloride-induced Cognitive Impairment", Clinical Psychopharmacology and Neuroscience, 18(2), pp.241~248 (2020), 대한정신약물학회[DOI]
- Smith D, "A systematic review of medication non-adherence in persons with dementia or cognitive impairment", PLoS One, 12, pp.e0170651~ (2017)
- Stoehr GP, "Factors associated with adherence to medication regimens in older primary care patients : the Steel Valley Seniors Survey", Am J Geriatr Pharmacother, 6, pp.255~263 (2008)
- Insel K, "Executive function, working memory, and medication adherence among older adults", J Gerontol B Psychol Sci Soc Sci, 61, pp.P102~ (2006)
- Cotrell V, "Medication management and adherence among cognitively impaired older adults", J Gerontol Soc Work, 47, pp.31~46 (2006)
- Heneka MT, "Neuroinflammation in Alzheimer’s disease", Lancet Neurol, 14, pp.388~405 (2015)
- Van Eldik LJ, "The roles of inflammation and immune mechanisms in Alzheimer’s disease", Alzheimers Dement(N Y), 2, pp.99~109 (2016)
- Kinney JW, "Inflammation as a central mechanism in Alzheimer’s disease", Alzheimers Dement(N Y), 4, pp.575~590 (2018)
- Goschorska M, "Effect of acetylcholinesterase inhibitors donepezil and rivastigmine on the activity and expression of cyclooxygenases in a model of the inflammatory action of fluoride on macrophages obtained from THP-1monocytes", Toxicology, 406-407, pp.9~20 (2018)
- Shifrin H, "Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses", PLoS One, 8, pp.e57668~ (2013)
- Wang LX, "M2b macrophage polarization and its roles in diseases", J Leukoc Biol, 106, pp.345~358 (2019)
- Hsieh SW, "M2b macrophage subset decrement as an indicator of cognitive function in Alzheimer’s disease", Psychiatry Clin Neurosci, 74, pp.383~391 (2020)
- Frankfort SV, "Identification of responders and reactive domains to rivastigmine in Alzheimer’s disease", Pharmacoepidemiol Drug Saf, 16, pp.545~551 (2007)
- McKeith I, "Efficacy of rivastigmine in dementia with Lewy bodies : a randomised, double-blind, placebo-controlled international study", Lancet, 356, pp.2031~2036 (2000)
- Gauthier S, "EXACT : rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer’s disease", Int J Clin Pract, 61, pp.886~895 (2007)
- Preuss UW, "Treatment of behavioral and psychological symptoms of dementia : a systematic review", Psychiatr Pol, 50, pp.679~715 (2016)
- Yang YH, "Framework of treating Alzheimer’s dementia", Brain Sci Adv, 5, pp.82~93 (2019)